FDA Approves Novo Nordisk's New Wegovy Injection

The FDA has approved Novo Nordisk's new Wegovy® HD injection, offering the highest weight loss efficacy achieved to date for a Wegovy® product. Clinical trials demonstrated an average weight loss of approximately 21% at 72 weeks in adults with obesity who remained on treatment. This advancement expands the therapeutic options for individuals managing obesity and further solidifies Wegovy's position in the market. The new formulation adds to the drug's already extensive clinical profile.